DSIP[Delta sleep-inducing peptide]
Compound snapshot
Class
Sleep-related neuropeptide
FDA approved
No — not FDA-approved for sleep or any other indication
Clinical development
Phase 2
Last reviewed
September 2026
Research areas
Sleep architecture / Circadian signalling / Neuroendocrine stress response
Regulatory status
Research use only — not FDA-approved
Internet attention
Moderate
Registry query
DSIP
A naturally occurring nine-amino-acid peptide first isolated in sleep research. Its biological role and the identity of a specific human receptor remain uncertain.
Reality check — what we actually know
Supported by human evidence
- A six-person double-blind crossover study reported acute and delayed changes in sleep measures.
- A 16-person double-blind insomnia study found weak effects and concluded that major therapeutic benefit was unlikely.
Animal research only
- Early animal experiments reported altered delta-wave and sleep patterns, with species-dependent responses.
Mechanistically plausible
- Sleep and neuroendocrine modulation have been proposed, but a validated therapeutic receptor mechanism remains uncertain.
Common internet claims
- "DSIP reliably produces deep sleep" — the small human studies were inconsistent and are not confirmatory.
Not established
- Clinical efficacy for insomnia
- Long-term safety
- Safety or potency of consumer-market products
Evidence distribution
Each band is a live PubMed search for DSIP, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
DSIP has been studied as a modulator of sleep architecture and stress-related neuroendocrine signalling, but a validated therapeutic mechanism in humans has not been established.
- Small early studies reported changes in sleep latency, efficiency or slow-wave sleep
- A double-blind study in 16 people with chronic insomnia found only weak effects and concluded that major therapeutic benefit was unlikely
- Most human studies are small, several decades old and used intravenous research administration
Strength of the evidence: Limited and inconsistent human evidence from small controlled studies, including a six-volunteer crossover experiment and a 16-person double-blind insomnia trial. There are no large modern confirmatory trials or FDA-approved indications.
Safety and known cautions
Long-term safety, interactions, product quality and effects from consumer-market routes are not established. Small historical studies cannot establish safety for unsupervised use.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2Current
- Phase 3
- Regulatory review
- Approved